ETNB
89bio, Inc.
$14.84
+0.00
(+0.00%)
Mkt Cap
2.20B
Volume
38,511,212
52W Range
4.16-15.06
Sector
Healthcare
Beta
1.26
EPS (TTM)
-3.61
P/E Ratio
-2.23
Revenue (TTM)
21,000
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (367.08M) | (142.19M) | (102.03M) | (90.12M) | (49.50M) | (57.42M) | (16.18M) |
| EPS | -3.51 | -2.00 | -2.93 | -4.48 | -3.08 | -5.40 | -3.53 |
| Free Cash Flow | (367.84M) | (129.19M) | (81.10M) | (76.84M) | (46.37M) | (25.60M) | (12.51M) |
| FCF / Share | -3.51 | -1.82 | -2.33 | -3.82 | -2.88 | -2.41 | -2.73 |
| Operating CF | (367.82M) | (129.19M) | (81.09M) | (76.78M) | (46.24M) | (25.46M) | (12.47M) |
| Total Assets | 478.69M | 596.27M | 196.82M | 162.42M | 211.07M | 95.55M | 11.37M |
| Total Debt | 37.55M | 27.11M | 20.55M | 19.40M | 0 | 0 | 24.74M |
| Cash & Equiv | 126.06M | 316.16M | 55.26M | 52.43M | 98.18M | 93.36M | 11.23M |
| Book Value | 400.79M | 536.31M | 151.83M | 125.96M | 202.96M | 89.94M | (16.06M) |
| Return on Equity | -0.92 | -0.27 | -0.67 | -0.72 | -0.24 | -0.64 | N/A |
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 21,000 | 0 | 0 | 0 | 234,000 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (111.50M) | (71.28M) | (118.35M) | (149.07M) | (47.97M) | (51.68M) | (40.23M) | (34.73M) | (38.39M) | (84.12M) | (24.60M) | (26.80M) |
| EPS | -0.71 | -0.49 | -1.02 | -1.39 | -0.48 | -0.54 | -0.50 | -0.45 | -0.52 | -1.58 | -0.48 | -0.57 |
| Free Cash Flow | (100.42M) | (71.81M) | (121.59M) | (145.36M) | (61.16M) | (39.72M) | (34.30M) | (30.36M) | (34.45M) | (30.09M) | (27.10M) | (14.81M) |
| FCF / Share | -0.64 | -0.62 | -1.05 | -1.36 | -0.61 | -0.41 | -0.43 | -0.40 | -0.46 | -0.57 | -0.53 | -0.31 |
| Operating CF | (100.42M) | (71.74M) | (121.58M) | (145.36M) | (61.16M) | (39.72M) | (34.29M) | (30.36M) | (34.45M) | (30.09M) | (27.10M) | (14.81M) |
| Total Assets | 603.49M | 685.03M | 478.69M | 458.30M | 582.14M | 577.32M | 596.27M | 460.11M | 492.51M | 494.32M | 196.82M | 200.58M |
| Total Debt | 37.62M | 37.58M | 37.55M | 37.57M | 27.35M | 27.30M | 27.11M | 24.87M | 24.75M | 24.64M | 20.55M | 20.19M |
| Cash & Equiv | 129.08M | 315.40M | 126.06M | 91.41M | 212.22M | 217.57M | 316.16M | 251.93M | 245.44M | 350.93M | 55.26M | 72.40M |
| Book Value | 521.73M | 605.46M | 400.79M | 378.10M | 514.92M | 510.54M | 536.31M | 410.21M | 441.99M | 445.83M | 151.83M | 152.57M |
| Return on Equity | -0.21 | -0.12 | -0.30 | -0.39 | -0.09 | -0.10 | -0.08 | -0.08 | -0.09 | -0.19 | -0.16 | -0.18 |
ETNB News
No news available for ETNB.